Send to

Choose Destination
Mol Immunol. 2011 Oct;49(1-2):290-6. doi: 10.1016/j.molimm.2011.08.020. Epub 2011 Sep 22.

Regulatory immune responses induced by IL-1 receptor antagonist in rheumatoid arthritis.

Author information

Department of Immunology, Institutes of Medical Sciences, Shanghai JiaoTong University School of Medicine, Shanghai institute of Immunology, Shanghai, PR China.


Anakinra, a human recombinant IL-1 receptor antagonist, is approved for the treatment of RA. In this study, 12 patients received the placebo plus MTX treatment, 38 patients received Anakinra combined with MTX treatment. Compared with the placebo plus MTX group, serum levels of IL-17, IFN-γ, IL-21 and IL-1β significantly decreased, the percentages of Th17 cells and Th1 cells were lower and the percentage of Treg cells was higher after receiving Anakinra combined with MTX treatment. The observed regulatory immune responses collectively correlated with clinical improvement in treated patients. A substantial response, ACR 20 at 24 w were consistent with those at 12 w, 16 w and 20 w, and was accompanied by a marked improvement in RA related laboratory parameters. The study reveals that the combination of Anakinra and MTX is safe and well tolerated, which induces regulatory immune responses and significantly provides greater clinical benefit than the placebo plus MTX group.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center